159 related articles for article (PubMed ID: 35349370)
1. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
Maron SB; Moya S; Morano F; Emmett MJ; Chou JF; Sabwa S; Walch H; Peterson B; Schrock AB; Zhang L; Janjigian YY; Chalasani S; Ku GY; Disel U; Enzinger P; Uboha N; Kato S; Yoshino T; Shitara K; Nakamura Y; Saeed A; Kasi PM; Chao J; Lee J; Capanu M; Wainberg Z; Petty R; Pietrantonio F; Klempner SJ; Catenacci DVT
J Clin Oncol; 2022 Aug; 40(22):2458-2467. PubMed ID: 35349370
[TBL] [Abstract][Full Text] [Related]
2.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
3.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
4. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
8. Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer.
Openshaw MR; Pinato DJ; Valeri N
Clin Cancer Res; 2021 Jun; 27(11):2964-2966. PubMed ID: 33771852
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
10. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
12. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
[TBL] [Abstract][Full Text] [Related]
14. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
15. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
Baxter MA; Spender LC; Cairns D; Walsh S; Oparka R; Porter RJ; Bray S; Skinner G; King S; Turbitt J; Collinson D; Miedzybrodzka ZH; Jellema G; Logan G; Kennedy RD; Turkington RC; McLean MH; Swinson D; Grabsch HI; Lord S; Seymour MJ; Hall PS; Petty RD
ESMO Open; 2024 May; 9(5):103450. PubMed ID: 38744099
[TBL] [Abstract][Full Text] [Related]
16. EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth EC; Vlachogiannis G; Hedayat S; Harbery A; Hulkki-Wilson S; Salati M; Kouvelakis K; Fernandez-Mateos J; Cresswell GD; Fontana E; Seidlitz T; Peckitt C; Hahne JC; Lampis A; Begum R; Watkins D; Rao S; Starling N; Waddell T; Okines A; Crosby T; Mansoor W; Wadsley J; Middleton G; Fassan M; Wotherspoon A; Braconi C; Chau I; Vivanco I; Sottoriva A; Stange DE; Cunningham D; Valeri N
Gut; 2021 Sep; 70(9):1632-1641. PubMed ID: 33199443
[TBL] [Abstract][Full Text] [Related]
17. Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival.
Chao J; Bedell V; Lee J; Li MS; Chu P; Yuan YC; Zhao D; Klempner SJ; Lin RJ
JAMA Netw Open; 2020 Apr; 3(4):e203652. PubMed ID: 32338752
[TBL] [Abstract][Full Text] [Related]
18. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
Malka D; François E; Penault-Llorca F; Castan F; Bouché O; Bennouna J; Ghiringhelli F; de la Fouchardière C; Borg C; Samalin E; Bachet JB; Raoul JL; Miglianico L; Bengrine-Lefèvre L; Dahan L; Lecaille C; Aparicio T; Stanbury T; Perrier H; Cayre A; Laurent-Puig P; Gourgou S; Emile JF; Taïeb J
Eur J Cancer; 2019 Jul; 115():97-106. PubMed ID: 31129386
[TBL] [Abstract][Full Text] [Related]
19. Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
Lau-Min KS; Li Y; Eads JR; Mamtani R; Getz KD
Cancer; 2022 May; 128(9):1853-1862. PubMed ID: 35119688
[TBL] [Abstract][Full Text] [Related]
20. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
